Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Further Reading from MarketBeat Media 2 Healthcare Names That Could Get a Big Boost From EarningsAuthor: Nathan Reiff. Publication Date: 1/20/2026. 
At a Glance - An acceleration from last quarter's 4% year-over-year growth in nutrition segment sales could help boost Abbott Laboratories' revenue performance.
- Intuitive Surgical's preliminary fourth-quarter earnings results led to a modest dip in share price, perhaps due to middling forecasted da Vinci procedure growth for 2026.
- Still, overall adoption and revenue growth rates remain high, and the temporary decline may be an opportunity for long-term investors.
Active traders expect companies in the healthcare sector to see meaningful share-price moves tied to milestones in the development of new therapies and medical products. The sector can be volatile—high risk but potentially high reward. Another catalyst for significant price movement is healthcare earnings reports. The two companies below may be positioned for near-term or longer-term upside depending on the signals their late-January earnings releases send. Analysts Expect Abbott to Overcome Nutrition Sluggishness A $211 billion healthcare giant, Abbott Laboratories (NYSE: ABT) provides diagnostics, medical devices, pharmaceuticals and more. The company is particularly known for its continuous glucose monitoring (CGM) systems and cardiovascular and vascular products. The former CEO of Google calls it the most important thing to happen in 500, maybe 1,000 years of human society. A former U.S. Treasury Secretary says when your great-grandchildren write the history of this period, the political headlines will be the second or third story. The first story is something none of us have seen before. The dot-com collapse, global financial crisis, and COVID-19 pandemic don't compare to what's coming next. We may be entering a period of dramatic, almost unimaginable change. See the full warning and how to prepare now. After some volatility, Abbott has produced a modest 4.3% gain over the past 12 months, underperforming the S&P 500. For the third quarter of 2025, Abbott met analyst expectations with earnings per share (EPS) of $1.30 but missed revenue by more than $31 million, even as sales rose roughly 7% year-over-year (YOY). Headwinds included Abbott's nutrition segment, which grew just 4% YOY, and weakness in the Chinese diagnostics market driven by tariffs and trade issues. Still, the somewhat lackluster top- and bottom-line results may mask strong areas of the business, such as a 17% YOY increase in CGM product sales to $2 billion. Investors will watch whether new high-protein, lower-sugar formulations of Ensure and Glucerna can reignite category growth and boost overall sales. Abbott's earlier problems with volume-based procurement in China suggest that challenges there may persist. However, strong performance in medical devices, pharmaceuticals and diagnostics outside China could offset those headwinds. Wall Street appears confident heading into the company's end-of-year earnings. Analysts at Barclays, Evercore ISI and others have reiterated Buy ratings or raised price targets recently. Overall, 19 analysts rate ABT a Buy versus four Holds, implying roughly 21% upside from current levels. Intuitive's Preliminary Earnings Dip Could Be a Hidden Opportunity Intuitive Surgical (NASDAQ: ISRG) is similar in scale to Abbott but focuses narrowly on robot-assisted surgical systems. Investors already have a preview of the company's fourth-quarter results from preliminary numbers released on Jan. 14, 2026. Driven by an aging population and rising demand for minimally invasive procedures, Intuitive reported total worldwide procedures rose 18% YOY for the quarter. Intuitive's da Vinci system continued its adoption trajectory, helping drive fourth-quarter revenue up 19% YOY to $2.87 billion. Despite these solid metrics, the market reacted to the preliminary release with a modest sell-off in ISRG shares. Part of the pullback likely reflected somewhat cautious 2026 guidance: Intuitive expects da Vinci procedures to grow 13%–15% in 2026, versus an 18% increase in 2025. Longer term, Intuitive's prospects remain strong thanks to continued demand for its systems and a pipeline of imaging agents and other therapeutics that investors sometimes overlook. If the official fourth-quarter report provides a fuller picture of the company's momentum heading into the year, shares could recover from the earlier dip. Analysts remain largely bullish in the near term: 18 rate ISRG a Buy versus nine combined Hold and Sell ratings, with consensus upside of more than 16%.
| 
